Loading clinical trials...

AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study

NCT01107340•Medacta International SA

Summary

This is a multicentre post-marketing prospective study to evaluate performance and clinical outcomes of AMIIStem primary hip system.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient is a good candidate for a primary hip arthroplasty using AMIStem Hip System
•Patient is willing and able to give informed consent to participate in the follow-up program
•Patient is suitable for surgery and able to participate in the follow-up program.
•Those presenting with disease that meets the indication for use for Medacta implants defined in the study (on-label use)

Exclusion Criteria

•Acute systemic or chronic infection
•Skeletal immaturity
•Severe muscular, neurological, vascular deficiency or other pathologies of the affected limb that may compromise the stability of the implant.
•Bone condition that may compromise the stability of the implant.
•Patient who are unwilling or unable to give consent, or to comply with the protocol and the follow-up program.

Locations (2)

Uniklinik Balgrist

Zurich, Switzerland

The Elective Orthopaedic Centre (EOC)

Epsom, Surrey, United Kingdom

Key Dates

Start Date

January 1, 2010

Primary Completion Date

January 1, 2028

Completion Date

January 1, 2028

Last Updated

December 16, 2024

Enrollment

500

ESTIMATED participants

Conditions

OsteoarthritisArthritisAvascular NecrosisFracture of the Femoral Neck or HeadCongenital Hip Dysplasia

Interventions

AMIStem Hip System

DEVICE

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

NCT07484243

Rheumatoid Arthritis (RA)Rheumatoid Arthritis-Associated Interstitial Lung Disease+1 more

View study

RECRUITING

Natural History and Development of Spondyloarthritis

NCT01422694

ArthritisSpondylitis, Ankylosing

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 16, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study

Inclusion Criteria

Exclusion Criteria

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

Natural History and Development of Spondyloarthritis

A Study of Picankibart in Patients With Active Psoriatic Arthritis

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis